News
13th February 2025
Immunosis recognised by Forbes magazine as a standout start up biotech company
Immunosis is delighted to be seletected by Forbes Magazine as a standout Australian start up biotechnology company. We were the first resident to move into the Jumar Bioincubator space in the new CSL building.
Dr. Simon Green, the CEO of Immunosis said "it is wonderful being part of such a vibrant ecosystem and so close to our key collarborating partners at the Royal Melbourne Hospital, Royal Children's Hospital and the Walter an Eliza Hall Institute for Medical Research"
The Jumar Bioincubator was founded by Australia’s own CSL, in conjunction with the University of Melbourne, WEHI and Breakthrough Victoria. It is managed by Cicada Innovations.
Here is the link to the article
16th December 2025
Recruitment Open for the IMM003 Trial – A Genomic Study on Bronchiectasis and Primary Immunodeficiency
We’re thrilled to announce that recruitment is now open for the IMM003 Trial: A Pilot Genomic Analysis of Patients with Bronchiectasis and Primary Immunodeficiency (PID).
This study aims to develop an advanced diagnostic method using genetic information to improve the detection of PID. If successful, this test could lead to faster diagnoses, enabling patients to access life-changing treatments and therapies sooner.
Many patients with PID develop bronchiectasis, and this research could significantly enhance our ability to distinguish PID among those with lung disease.
We’re proud to collaborate once again with the incredible teams at the Royal Melbourne Hospital and WEHI to drive this important work forward.
For more information, reach out to any of our Immunosis team.
15th October 2024
Immunosis awarded Stage 2 funding under ANDHealth+ Program
After successful completion of a Stage 1 project to evaluate the clinical utilty, commercial opportunity and market access, Immunosis has been invited to participate in Stage 2 funding. Under the ANDHealth+ program, five of Australia's best digital health companies will share in $3.25m AUD funding, supported by the Medical Research Future Fund (MRFF).
28th May 2024
Immunosis attends Clinical Immunology Society Annual Meeting in Minneapolis to present additional data from clinical study
The entire Immunosis team was in Minneapolis this May to attend the Clinical Immunology Society Annual Meeting. Our CSO, Ben Cocks, presented our results alongside Senior Scientist Emma Gail during a lively poster session. You can read our abstract below or through the Clinical Immunology supplement link:
https://www.sciencedirect.com/science/article/abs/pii/S1521661624001785
25th August 2023
Boost for Immunosis to commercialise diagnosis of diseases driven by immune dysregulation
We are pleased to announce Immunosis has been selected as a recipient of the highly competitive ANDHealth+ award for 2023.
Immunosis is delighted to work with ANDHealth to further develop and commercialise our technology including our lead product, PrimDx, a diagnostic test for patients with primary immunodeficiency.
We are working to establish our RNA-based platform technology for understanding and diagnosing diseases driven by immune dysregulation. As part of the ANDHealth+ program, Immunosis plans to conduct a clinical validation study in Australia and the USA in patients prone to repeated sinus and respiratory infections and develop a reimbursement strategy to offset the cost of testing for patients. These steps are critical for the commercialisation of PrimDx in global markets.
The ANDHealth+ program supports and funds digital health companies such as Immunosis to accelerate commercialisation of their platforms. The program is funded by the Australian Government’s Medical Research Future Fund (MRFF).
For more information, please visit the following link:
Read a statement from our CEO, Simon Green, here as well as about the program: https://www.andhealth.com.au/news/five-promising-digital-health-companies-selected-to-scale-exciting-new-australian-health-technologies
19th June 2023
Immunosis presents latest data at CIS 2023
CSO Prof. Ben Cocks and senior scientist Dr Emma Gail attended the Clinical Immunology conference in St. Louis this year, learning about the latest research in the field and meeting with leading clinicians and researchers. Dr Gail presented the work from our first clinical study in the poster titled “Identifying patients with primary immunodeficiency using statistical modelling of unique genetic signatures from transcriptomic data” You can view the full poster here:
Read our abstract published in the supplement in the May 2023 issue of Clinical Immunology: https://www.sciencedirect.com/science/article/pii/S1521661623002656
29th March 2023
Immunosis presenting and looking to collaborate at CIS 2023
Immunosis' Senior Scientist Dr Emma Gail and CSO Prof Ben Cocks will be attending the 2023 Clinical Immunology Society meeting in St Louis MO USA May 18-21.
Dr Gail will be presenting data on the potential of transcriptomics to better identify and characterise patients with Primary Immune Deficiency (PID).
The new results for our diagnostic test, Prim-Dx, have been generated through collaborations with the Walter and Eliza Hall Institute of Medical Research, Royal Children’s Hospital, Murdoch Children’s Research Institute, and the Royal Melbourne Hospital.
Immunosis CEO Dr Simon Green said “Immunosis are looking forward to welcoming discussion with leading clinicians and investigators on expanding transcriptomic studies for PID complementing other clinical studies".
Abstract is titled: Using statistical modelling to better identify primary immunodeficiency using a unique genetic signature from transcriptomic data
Immunosis has appointed Professor Ben Cocks as Chief Scientific Officer.
2nd June 2022
The Hon Jaala Pulford announced today a grant of $100k to fund clinical trial work with the aim of developing the Immunosis diagnostic technolgy for patients with Primary Immune Deficiency.
Both patients and healthy controls are currently being recruited for the study.
https://www.premier.vic.gov.au/site-4/faster-diagnosis-possible-new-clinical-trial
